Myriad Genetics, Inc. has announced new clinical data from the MONSTAR-SCREEN 3 study, conducted in collaboration with the National Cancer Center Hospital East in Japan. The study demonstrated the effectiveness of Myriad's Precise™ MRD Test in detecting and monitoring circulating tumor DNA (ctDNA) across multiple cancer types. The results, presented at the 2025 ASCO Annual Meeting, showed 100% detection of ctDNA at baseline and indicated that 60% of patients tested positive for ctDNA one month after surgery, with tumor fractions detectable only through the ultra-sensitive test. The Precise MRD Test, informed by whole-genome sequencing, tracks numerous tumor-specific sites, enhancing sensitivity even in cancers with low shedding tumors. Findings suggest that ctDNA clearance during neoadjuvant chemotherapy predicts a pathological complete response, and patients with ultra-sensitive ctDNA positive results post-surgery had worse disease-free survival.